Norfloxacin Online |
|
How and where to order Norfloxacin (Noroxin) 100, 200, 400 mg tablets or capsules online:
 Norfloxacin (trade names include Noroxin, Baccidal, Floxatral, Floximed, Fortimax, Fulgram, Gyrablock, Lexinor, Nolicin, Norbactin, Norflohexal, Norfloxacin Sandoz, Norfloxacine Arrow Generiques, Noroxine, Norxacin, Nufloxib, Oranor, Quinoform, Respexil, Trizolin, Uritrat, Urobacid, Uroctal, Uroseptal, Zoroxin) is an antibacterial medication from fluoroquinolones pharmacological group. This medicine is used to treat various bacterial infections, including eye, ear, prostate, bladder, urinary tract, kidney, gynecological infections, epididymitis, cystitis, gastroenteritis, traveler's diarrhea, shigellosis, prostatitis, conjunctivitis, otitis, typhoid fever, paratyphoid fever, some sexually transmitted diseases such as syphilis, urethral and cervical gonorrhea, for prevention of spontaneous bacterial peritonitis, in veterinary medicine. Norfloxacin works by killing sensitive bacteria.
Related medications: Pharmacological and medical categories: ATC codes: ICD-10 codes: Indications and usage: Noroxin (Norfloxacin) is indicated for the treatment of adults with the following infections caused by susceptible strains of the designated microorganisms: Urinary tract infections Uncomplicated urinary tract infections (including cystitis) due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, Staphylococcus saprophyticus, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Proteus vulgaris, Staphylococcus aureus, or Streptococcus agalactiae. Complicated urinary tract infections due to Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, or Serratia marcescens. Sexually transmitted diseases Uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae. Prostatitis Prostatitis due to Escherichia coli. Penicillinase production should have no effect on norfloxacin activity. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to norfloxacin. Therapy with norfloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be given. Repeat culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agents but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Noroxin and other antibacterial drugs, Norfloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. W hen culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Contraindications: Noroxin (Norfloxacin) is contraindicated in persons with a history of hypersensitivity, tendinitis, or tendon rupture associated with the use of norfloxacin or any member of the quinolone group of antimicrobial agents. Dosage and administration: Norfloxacin (Noroxin) tablets should be taken at least one hour before or at least two hours after a meal or ingestion of milk and/or other dairy products. Multivitamins, other products containing iron or zinc, antacids containing magnesium and aluminum, sucralfate, or Videx (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution, should not be taken within 2 hours of administration of norfloxacin. Noroxin pills should be taken with a glass of water. Patients receiving this medication should be well hydrated. Overdosage: No significant lethality was observed in male and female mice and rats at single oral doses of norfloxacin up to 4 g/kg. In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage, and the patient carefully observed and given symptomatic and supportive treatment. Adequate hydration must be maintained. Warnings: Precautions: Needle-shaped crystals were found in the urine of some volunteers who received either placebo, 800 mg norfloxacin, or 1600 mg norfloxacin (at or twice the recommended daily dose, respectively) while participating in a double-blind, crossover study comparing single doses of norfloxacin with placebo. W hile crystalluria is not expected to occur under usual conditions with a dosage regimen of 400 mg b.i.d., as a precaution, the daily recommended dosage should not be exceeded and the patient should drink sufficient fluids to ensure a proper state of hydration and adequate urinary output. Alteration in dosage regimen is necessary for patients with impaired renal function. Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, "V" area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of quinolone antibiotics after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if phototoxicity occurs. Rarely, hemolytic reactions have been reported in patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity who take quinolone antibacterial agents, including norfloxacin. Prescribing Noroxin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Adverse reactions, side effects: The most common adverse experiences ( > 1.0%) were: Additional reactions (0.3%-1.0%) were: Use in specific populations: Pregnancy Teratogenic Effects: Norfloxacin has been shown to produce embryonic loss in monkeys when given in doses 10 times2 the maximum daily total human dose (on a mg/kg basis). At this dose, peak plasma levels obtained in monkeys were approximately 2 times those obtained in humans. There has been no evidence of a teratogenic effect in any of the animal species tested (rat, rabbit, mouse, monkey) at 6-50 times the maximum daily human dose (on a mg/kg basis). There are, however, no adequate and well-controlled studies in pregnant women. Norfloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers It is not known whether norfloxacin is excreted in human milk. When a 200 mg dose of Noroxin was administered to nursing mothers, norfloxacin was not detected in human milk. However, because the dose studied was low, because other drugs in this class are secreted in human milk, and because of the potential for serious adverse reactions from norfloxacin in nursing infants, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use The safety and effectiveness of oral norfloxacin in pediatric patients and adolescents below the age of 18 years have not been established. Norfloxacin causes arthropathy in juvenile animals of several animal species. Geriatric Use Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as Noroxin. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing Noroxin (Norfloxacin) to elderly patients, especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue Noroxin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur. Pregnancy categories: Salts and other forms: Synonyms, international and chemical names: Brands, generics, trade names: APIs used in medicine in combinations with norfloxacin: Here is a list of popular medications containing norfloxacin as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
References: Updated: November 2020 Reviewed: November 2020 |